| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780184 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
For patients with endometrial cancers with stage I-III risk factors, adjuvant CRT can significantly improve PFS and CSS compared with RT. With the exception of increased acute toxicities, CRT is well accepted and tolerated in HREC patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lilan Yi, Hongman Zhang, Jingwen Zou, Peng Luo, Jian Zhang,